Revolutionary kit promises faster, cheaper, and more accurate detection of respiratory diseases like tuberculosis and asthma using homegrown technology.
In a significant scientific breakthrough, Indian researchers have developed a new indigenous immunodiagnostic kit that can simplify the diagnosis and treatment process for asthma and tuberculosis (TB) — two of the most pressing respiratory diseases affecting millions in India and across the globe. The kit, developed using 100% indigenous technology, is expected to drastically reduce testing costs and improve early detection outcomes, especially in rural and underserved regions.
🔬 Developed by Indian Scientists with Global Vision
The pioneering effort was led by a multidisciplinary team of Indian scientists from leading institutions, including the Indian Council of Medical Research (ICMR) and CSIR-IGIB (Institute of Genomics and Integrative Biology). After over three years of intensive research, the team has succeeded in producing a robust, sensitive, and affordable diagnostic solution for asthma and TB using protein-based immunoassay technology.
Dr. Renu Sharma, project lead and immunologist at ICMR, said:
“Our aim was to develop a low-cost yet high-accuracy tool to detect immune responses specific to respiratory infections like TB and asthma. The new kit provides reliable results in less than an hour.”
💡 What is an Immunodiagnostic Kit?
An immunodiagnostic kit works by detecting immune system biomarkers — such as antibodies or antigens — present in a patient’s blood, sputum, or other bodily fluids. In the context of asthma and TB, it identifies inflammatory proteins or TB-specific antigens that indicate the presence and severity of disease.
Unlike conventional methods like chest X-rays, sputum culture tests, or Mantoux skin tests, this kit offers a non-invasive, faster, and highly specific alternative.
🌟 Key Features of the New Kit
-
✅ 100% Made in India – No foreign components or patented technologies used
-
✅ Dual detection – Can differentiate between asthma and tuberculosis indicators
-
✅ Time-efficient – Results in 45–60 minutes
-
✅ High accuracy – >95% sensitivity for both conditions
-
✅ Portable & user-friendly – Ideal for rural health centers and mobile clinics
-
✅ Affordable – Estimated cost per test: ₹150–₹200, much lower than existing private lab tests
🫁 Why This Matters: India’s Respiratory Disease Burden
India bears the highest global burden of tuberculosis, accounting for over 25% of all TB cases worldwide, according to the WHO Global TB Report 2023. Asthma, though less fatal, affects over 34 million Indians, causing missed workdays, school absenteeism, and reduced quality of life.
Many cases of asthma and TB go undiagnosed or are misdiagnosed, especially in semi-urban or rural regions where access to diagnostic labs is poor. The new immunodiagnostic kit aims to bridge this gap by bringing testing closer to the patient.
🧪 Trials and Validation
The diagnostic kit has undergone multi-phase clinical validation trials at public hospitals and research institutions in Delhi, Mumbai, and Bengaluru. Over 2,500 patients were enrolled for the study, and the kit’s accuracy was benchmarked against existing gold-standard tests.
Dr. Naresh Kulkarni, pulmonologist at AIIMS Delhi, stated:
“In our trials, the kit not only matched standard TB detection rates but also helped confirm complex asthma cases that were misdiagnosed as chronic bronchitis.”
🚀 What’s Next: Mass Production & Rural Rollout
The Department of Biotechnology and Ministry of Health have approved funding for mass-scale production through a collaboration with a leading Indian biotech company. Distribution to government hospitals and PHCs (Primary Health Centres) is expected to begin by early 2026, with special training for rural healthcare workers.
Moreover, the kit has been submitted to the WHO Prequalification Program, which would allow it to be adopted in other low- and middle-income countries suffering from similar disease burdens.
🧬 Indigenous Innovation, Global Impact
India’s development of this kit underlines the country’s growing scientific capabilities and the Atmanirbhar Bharat initiative, promoting self-reliance in healthcare technology. It also highlights a shift in approach — from reactive treatment to proactive diagnosis and disease control.
Dr. Anita Rathi, a biotech policy expert, remarked:
“This breakthrough reflects how Indian innovation can solve global health challenges. More importantly, it brings dignity and accessibility to the most vulnerable patients.”
🌍 Potential Global Uses
The World Health Organization has already expressed interest in evaluating the kit for use in Africa and Southeast Asia, where TB continues to claim lives at alarming rates. With slight modifications, the technology may also be adapted to detect other inflammatory lung conditions, including COPD, post-COVID complications, and bronchitis.
✅ Conclusion
The new indigenous immunodiagnostic kit represents a paradigm shift in the fight against asthma and tuberculosis. Affordable, accurate, and built to serve the grassroots, it has the potential to transform respiratory disease management in India and beyond.
By reducing diagnostic delays and making detection easier, India takes a significant step closer to its vision of eliminating TB by 2025 and improving asthma care nationwide.